The 'Vascular Depression' hypothesis posits that cerebrovascular disease may predispose, precipitate or perpetuate some geriatric depressive syndromes. This hypothesis stimulated much research that has improved our understanding of the complex relationships between late-life depression (LLD), vascular risk factors, and cognition. Succinctly, there are well-established relationships between LLD, vascular risk factors and cerebral hyperintensities, the radiological hallmark of vascular depression. Cognitive dysfunction is common in LLD, particularly executive dysfunction, a finding predictive of poor antidepressant response. Over time, progression of hyperintensities and cognitive deficits predicts a poor course of depression and may reflect underlying worsening of vascular disease. This work laid the foundation for examining the mechanisms by which vascular disease influences brain circuits and influences the development and course of depression. We review data testing the vascular depression hypothesis with a focus on identifying potential underlying vascular mechanisms. We propose a disconnection hypothesis, wherein focal vascular damage and white matter lesion location is a crucial factor, influencing neural connectivity that contributes to clinical symptomatology. We also propose inflammatory and hypoperfusion hypotheses, concepts that link underlying vascular processes with adverse effects on brain function that influence the development of depression. Testing such hypotheses will not only inform the relationship between vascular disease and depression, but also provide guidance on the potential repurposing of pharmacological agents that may improve LLD outcomes.
INTRODUCTION
There is a substantial heterogeneity in the biological factors that influence the risk of developing depression across the lifespan. Genetic and epigenetic factors influence gene expression or protein function across a variety of molecular systems, resulting in a vulnerability to develop depression in context of psychosocial adversity. 1 This heterogeneity is even more apparent in depression occurring in older adults, or late-life depression (LLD), as aging-related changes across multiple organ systems also contribute to depression. Aging-related changes in the neurological, immune and endocrine systems have all been implicated in depression, but one of the best studied changes in LLD is the role of vascular disease.
The 'Vascular Depression' hypothesis proposed that 'cerebrovascular disease may predispose, precipitate or perpetuate some geriatric depressive syndromes'. 2 The hypothesis was accompanied by two proposals on the core characteristics of and how to define a vascular depression subtype. First, Alexopoulos and colleagues 2, 3 proposed a working definition based on the presence of vascular risk factors. The clinical presentation of 'vascular depression' was characterized by cognitive deficits, psychomotor retardation, lack of insight and disability disproportional to the depression severity. Investigators subsequently focused on the cognitive dysfunction occurring in LLD and its relationship to response to antidepressants. 4 Second, Krishnan and colleagues 5 proposed a magnetic resonance imaging (MRI)-based definition, requiring evidence of vascular changes on neuroimaging, referred to as MRI hyperintensities. Both definitions are important as subsequent work demonstrated the internal validity of a vascular depression diagnostic subtype characterized by MRI findings and executive dysfunction. 6 
WHITE MATTER LESIONS, WHITE MATTER HYPERINTENSITIES AND MRI-DEFINED VASCULAR DEPRESSION
The hallmark of MRI-defined vascular depression is the presence of white matter lesions (WMLs) identified as white matter hyperintensities (WMH) on T2-weighted or fluid-attenuated inversion recovery MRI. Throughout this review we refer to the radiological findings as WMHs, while reserving the term WML when discussing the underlying changes in the cerebral white matter. WMHs are associated with advanced age 7 and cerebrovascular risk factors, including diabetes, cardiac disease and hypertension. [8] [9] [10] [11] [12] Vascular dysregulation contributes to WMH development, as white matter is sensitive to transient ischemia, 13 and many larger WMHs are ischemic in origin. 14, 15 Hypertension and blood pressure variability are associated with LLD [16] [17] [18] and also contribute to WMH development, 19, 20 particularly when accompanied by impaired cerebral vasomotor reactivity and altered autoregulatory processes. 21, 22 Such deficits reduce cerebral blood flow (CBF) and may lead to WMHs.
Objective: Genetic factors confer risk for neuropsychiatric phenotypes, but the polygenic etiology of these phenotypes makes identification of genetic culprits challenging. An approach to this challenge is to examine the effects of genetic variation on relevant endophenotypes, such as hippocampal volume loss. A smaller hippocampus is associated with gene variants of the reninangiotensin system (RAS), a system implicated in vascular disease. However, no studies to date have investigated longitudinally the effects of genetic variation of RAS on the hippocampus.
Method:
The authors examined the effects of polymorphisms of AGTR1, the gene encoding angiotensin-II type 1 receptor of RAS, on longitudinal hippocampal volumes of older adults. In all, 138 older adults (age $60 years) were followed for an average of about 4 years. The participants underwent repeated structural MRI and comprehensive neurocognitive testing, and they were genotyped for four AGTR1 single-nucleotide polymorphisms (SNPs) with low pairwise linkage disequilibrium values and apolipoprotein E (APOE) genotype.
Results: Genetic variants at three AGTR1 SNPs (rs2638363, rs1492103, and rs2675511) were independently associated with accelerated hippocampal volume loss over the 4-year follow-up period in the right but not left hemisphere. Intriguingly, these AGTR1 risk alleles also predicted worse episodic memory performance but were not related to other cognitive measures. Two risk variants (rs2638363 and rs12721331) interacted with the APOE4 allele to accelerate right hippocampal volume loss.
Conclusions: Risk genetic variants of the RAS may accelerate memory decline in older adults, an effect that may be conferred by accelerated hippocampal volume loss. Molecules involved in this system may hold promise as early therapeutic targets for late-life neuropsychiatric disorders.
Am J Psychiatry Zannas et al.; AiA: [1] [2] [3] [4] [5] [6] [7] [8] Genet ic factors have long been hypothesized to confer risk for neuropsychiatric phenotypes, but it has been challenging to identify genetic culprits. The failure to identify risk genes may be in large part a result of the polygenic etiology and phenotypic heterogeneity of neuropsychiatric disorders (1) . These disorders result from complex interactions among multiple genes, tissue-specific epigenetic regulation, and environmental influences, which make identifying the relationships between single genes and distal phenotypes challenging.
An alternative approach is to examine endophenotypes, measurable constructs that confer risk for complex disorders and are thought to lie in greater etiological proximity to genetic factors (2) . One promising endophenotype for late-life neuropsychiatric disorders is small hippocampal volume (3) . Smaller hippocampal volume has been associated with treatment resistance in late-life depression (4) and predicts progressive cognitive decline in elderly individuals (5) . Therefore, efforts to link hippocampal volume reduction with risk genes may be particularly relevant for late-life neuropsychiatric syndromes.
A novel and biologically plausible gene to investigate in these relationships is AGTR1, the gene encoding angiotensin-II type 1 (AT 1 ) receptor in humans. AT 1 receptors are the primary effector of the renin-angiotensin system (RAS) in several organs, including the brain. The RAS is an important regulator of the stress response, and AT 1 receptors are expressed in brain regions that modulate stress and emotion, including the hypothalamus, amygdala, and hippocampus (6, 7) . In animal studies, RAS activation leads to hyperactivity of the stress system and heightened anxious behavior, whereas blockade of AT 1 receptors dampens stress responses and ameliorates anxious and depressive behavior (6, 8) . As the RAS also plays a central role in blood pressure regulation and has been implicated in vascular disease (9) , examining this system may be particularly relevant for older adults with depression, since late-life depression is often characterized by vascular comorbidity (10) .
Despite these theoretical implications, few studies have examined the relationship between genetic variation in AGTR1 and either neuropsychiatric phenotypes or hippocampal morphology. Studies on the common rs5186 AGTR1 (A-to-C) polymorphism have reported antidepressant response differences between genotypes in elderly depressed individuals (11) (12) (13) . In a broader analysis of single-nucleotide polymorphisms (SNPs) in AGTR1 (14) , our group reported that allele frequency differences in two AGTR1 SNPs increased the odds of late-life depression. We also found crosssectional associations between right hippocampal volume and four AGTR1 intronic SNPs, namely rs2638363, rs1492103, rs2675511, and rs12721331 (14) . To our knowledge, no studies have examined the effects of AGTR1 polymorphisms on longitudinal changes in hippocampal morphology in older adults. This is particularly important as reduction in hippocampal volume is associated with subsequent cognitive decline (5) .
To extend our previous findings demonstrating crosssectional relationships between AGTR1 and hippocampal morphology (14) , we examined the effects of AGTR1 genotype on longitudinal change in hippocampal volume. Our a priori hypothesis was that the gene variants we previously associated with smaller cross-sectional hippocampus volume would also be associated with greater hippocampal volume loss over time. We also sought to determine if these gene variants were associated with differences in cognitive function over time, particularly in domains involving the hippocampus, such as episodic memory. To control for the effects of depression that have been shown to lead to smaller hippocampal volumes via chronic hyperactivity of the stress system (15), we examined two cohorts of elderly depressed and nondepressed individuals. In secondary analyses, we examined whether depression diagnosis or apolipoprotein E (APOE) genotype had synergistic effects with AGTR1 genotypes on hippocampal volume change.
Method

Study Participants and Clinical Care
All participants were age 60 years or older and participated in the Conte Center for the Neuroscience of Depression in Late Life and the Neurocognitive Outcomes of Depression in the Elderly studies conducted at Duke University Medical Center. The Duke University Medical Center institutional review board approved these studies, and eligible individuals provided written informed consent.
The two cohorts were made up of depressed patients and nondepressed comparison subjects. Depressed patients were recruited primarily by clinical referral and secondarily by advertisements, and they met DSM-IV criteria for major depressive disorder. Diagnosis was based on the NIMH Diagnostic Interview Schedule (DIS) (16) and was confirmed by a geriatric psychiatrist during baseline clinical evaluation. Nondepressed individuals were community dwelling older adults recruited either from the Duke University Aging Center Subject Registry or through advertisements. All particpants underwent cognitive screening with the Mini-Mental State Examination (MMSE) (17) . Medical comorbidity was assessed with a previously used self-report questionnaire (18) .
Exclusion criteria for all individuals were as follows: 1) presence of other major psychiatric disorder such as schizophrenia or bipolar disorder; 2) history of substance abuse or dependence; 3) presence of neurological disease; 4) metal in the body or other contraindication for MRI; and 5) a screening MMSE score lower than 25. Furthermore, nondepressed individuals were excluded if they had evidence of past psychiatric disorder based on the DIS.
Antidepressant treatment followed the Duke Somatic Treatment Algorithm for Geriatric Depression (19) , which allows stepwise use of commercially available antidepressant modalities. The majority of depressed patients were prescribed sertraline on study entry, but treatment differed among participants and was guided by previous medication trials and depression severity. Following failed trials, switches to other antidepressant agents and augmentation strategies were allowed as clinically indicated. Treatment alternatives included psychotherapy and electroconvulsive therapy.
The current longitudinal study extends our past research (14) , where in a separate cohort we found a relationship between four AGTR1 SNPs and right hippocampal volumes. Although there was some overlap in participants, the present sample is much larger (138 compared with 70 individuals) and imaging data differ from our previous study. The previous study used 3-T MRI data; the present study used 1.5-T MRI data, as longitudinal 3-T data were not available for the majority of participants. Similar to our previous report and based on research showing racial differences in AGTR1 allele frequencies (14, 20) , we limited the current analyses to Caucasian individuals who had genotype data for all four AGTR1 SNPs and at least two hippocampal volume measurements (a baseline and at least one follow-up measurement).
Neuropsychological Assessments
Neuropsychological testing was administered to study participants at baseline and then annually, regardless of the presence or absence of depressive symptoms. The battery is described fully elsewhere (21) and has been successfully employed in a number of clinical and epidemiological settings (22) . Testing was administered by a trained psychometric technician supervised by a licensed clinical psychologist.
We created composite variables from the broader neuropsychological test battery that represented cognitive domains that may be adversely affected by aging. This was achieved by grouping neuropsychological tests into rational constructs, similar to previously published studies (23) . We created Z scores for each measure based on the performance of all participants and summed the Z scores for all tests within each domain. Internal consistency for each domain was assured using Cronbach's coefficient alpha. Following this approach, we created four composite neurocognitive measures: 1) episodic memory (logical memory, Benton visual retention test, immediate word learning, and word list recall; Cronbach's coefficient alpha=0.88); 2) executive speed (speed in Trails A and Trails B and symbol-digit modality test; Cronbach's coefficient alpha=0.86); 3) verbal fluency (verbal fluency test and controlled oral word association test; Cronbach's coefficient alpha=0.74); and d) working memory (digits forward, digits backward, and digits ascending; Cronbach's coefficient alpha=0.74).
Genotyping and Genetic Analyses
All genotyping was performed on DNA from whole peripheral blood using the Gentra PureGene system (Qiagen, Valencia, Calif.). Assays employed quality control procedures, which included serial genotyping of blinded duplicate samples. Quality requirements for each assay were met only if duplicate samples matched 100%, and efficiency of 95% was further required for each assay before statistical analyses. Deviations from HardyWeinberg equilibrium were previously tested for all SNPs separately in the depressed and nondepressed cohorts (14) using exact tests per the Genetic Data Analysis program (24) . Genotyped SNPs were identified using Linkage Disequilibrium Select (25) . Selected SNPs had linkage disequilibrium of r 2 ,0.64
and minor allele frequency of at least 0.10 in the HapMap project (www.hapmap.org), which was based on Utah residents of European ancestry and provided genetic coverage of the entire AGTR1. In this study, we focused on the four SNPs that displayed significant cross-sectional relationships with hippocampal volumes among the 10 SNPs tested in our previous report (14) . To examine whether these four SNPs could be treated as independent signals in our analyses, we estimated the pairwise linkage disequilibrium between all SNPs in our study population. All pairwise r 2 values were found to be below 0.5. APOE genotype was determined using previously published methods (26) .
MRI Acquisition and Analysis
Each participant was screened for contraindications and scanned with a 1.5-T whole-body MRI system (Signa, GE Medical Systems, Milwaukee) approximately every 2 years. All acquisitions were performed with the standard head (volumetric) radiofrequency coil. Using a previously described MRI acquisition protocol (27, 28) , we first confirmed alignment by a rapid sagittal localizer scan and then obtained two dual-echo fast spin-echo acquisitions: one in the axial plane for cerebral morphometry and one in a coronal oblique plane for hippocampal morphometry.
The images were then analyzed at the Duke Neuropsychiatric Imaging Research Laboratory. Segmentation of tissue and measurement of total cerebral volume, which included total white and gray matter and CSF volumes in both hemispheres, were performed as previously described (27) . Image analysts received extensive training, and reliability was established before any data processing by repeated measurements on multiple MRIs separated by at least a week. Intraclass correlation coefficients were as follows: left hippocampus=0.8; right hippocampus=0.7; and total cerebral volume=0.997.
Delineation of the hippocampus was based on previously described methods (28) . Analysts began with the most posterior coronal slice and moved anteriorly, measuring the hippocampus where the pulvinar nucleus of the thalamus obscured the crura fornicis on each side. The fimbria and the thin strip of gray matter along the medial border of the hippocampus were transected at their narrowest points. Tracing continued around the hippocampal body to the starting point. The anterior border of the hippocampus was defined as the slice on which the inferolateral ventricle appeared horizontally without any body of gray matter visible below it. The amygdala-hippocampal transition zone, which was transected at its narrowest point, appeared as a diffuse area of gray matter between the anterior portion of the hippocampus and the posterior portion of the amygdala.
Statistical Analyses
All statistical tests were performed with SAS, version 9.2 (Cary, N.C.). The level of statistical significance was set a priori at a=0.05 and all tests were two tailed. To maximize power in our analyses, we dichotomized each SNP into two genotype groups, the major allele homozygotes and the minor allele carriers. This further increased comparability with our previous report (14) , where the same genotype groups were used. The two diagnostic cohorts (depressed and nondepressed) were compared at baseline for differences in demographic variables and baseline measures. Categorical variables were compared with chi-square tests, equalvariance continuous variables with pooled two-sample t tests, and unequal-variance continuous variables with Satterthwaite t tests.
We next examined the longitudinal effects of AGTR1 polymorphisms on hippocampal volumes and composite cognitive measures. We used linear mixed-effects models (29) using the PROC MIXED command in SAS 9.3 to analyze these longitudinal data. Analyses included the maximum number of participants with data for longitudinal time points and for all variables included in the models. In these models, each individual was the independent sampling unit, and each measurement at a particular time point was the observation unit. Separate models were created for the right and left hippocampus and for each composite cognitive measure, with each AGTR1 SNP genotype group, time (as a continuous variable), and genotype-by-time interaction as the main independent variables. In order to account for betweensubject variability in brain volume, we included cerebral volume as a covariate in models that used hippocampal volume as the dependent variable. Other covariates included in all models were sex, age, diagnostic group (depressed or nondepressed), and the respective baseline hippocampal volume or cognitive measurement. The primary effects of interest were the genotype main effect, which examines the genotype effect irrespective of time, and the genotype-by-time interaction, which examines the rate of change in the mean hippocampal volume or cognitive measure over time between the two genotype groups for each AGTR1 SNP. Secondary analyses tested the three-way depression-bygenotype-by-time interaction and the AGTR1 genotype-by-APOE genotype-by-time interaction. All models were initially run with the interaction terms, and these terms remained in the model if significant, but were excluded if nonsignificant.
Results
Sample Demographics and Baseline Measures
The primary sample included 138 elderly individuals (79 depressed and 59 nondepressed) with genotype data for AGTR1 SNPs and at least two MRI scans (a baseline and one follow-up assessment). The demographic characteristics and clinical data are summarized in Table 1 . Their ages ranged from 60 to 84 years for the depressed cohort and from 60 to 82 years for the nondepressed cohort. The two groups were similar in genotype frequencies, age, MMSE scores, and baseline left and right hippocampal volumes. However, the percentage of female participants and educational levels were higher in the nondepressed group, and the percentage of patients who reported hypertension was higher in the depressed group. Finally, we found that the number of patients who reported a history of either cardiac complaints or hypertension did not significantly differ between the four AGTR1 or APOE genotype groups (data not shown). The maximum number of MRI measures per participant was five, and no significant difference was found for length of study follow-up between diagnostic cohorts (a mean of 1,435.3 days [SD=502.5] for depressed patients and a mean of 1,495.9 days [SD=785.8] for nondepressed patients; Satterthwaite t test=130, df=2, t=0.55, p=0.5855).
Longitudinal Effects of AGTR1 SNPs on Hippocampal Volumes
We created mixed models examining hippocampus volume in the left or right hemisphere as repeatedly measured dependent variables. Independent variables included diagnosis (depressed or nondepressed), age, sex, cerebral volume, baseline hippocampal volume, time, and AGTR1 SNP genotype. To test the hypothesis that SNPs would differentially affect hippocampal volume over time, we included a SNP-by-time interaction term. Table 2 summarizes the effects of the four AGTR1 SNPs examined and their interactions with time on left and right hippocampal volumes. When examining models of right hippocampal volume, three of the four SNPs (rs2638363, rs1492103, rs2675511) showed both a statistically significant primary effect and an interactive effect with time ( Table 2 ). The primary effect of AGTR1 SNPs replicated our previous findings (14) , despite nearly double the sample size and different MRI field strength. Again, individuals homozygous for the vascular risk alleles (rs2638363 GG, rs1492103 TT, and rs2675511 AA) exhibited smaller hippocampal volumes when compared with individuals who were heterozygous or homozygous for the alternate allele. The SNP-by-time interaction tested for differences between SNP alleles on change in hippocampal volume over time. When examining these interactions, individuals homozygous for the risk alleles exhibited an accelerated decrease in right hippocampal volume over time relative to individuals with alternate genotypes. However, the four SNPs exhibited neither a significant primary effect nor a significant gene-by-time interaction on left hippocampal volume. In other words, the effect of all three SNPs was selective and lateralized to the right hemisphere.
In secondary analyses we tested whether AGTR1 genetic variation has synergistic effects with depression or APOE genotype on the rate of hippocampal volume change. The three-way depression-by-AGTR1-by-time interactions did not reach significance for any of the SNPs for either the left or right hippocampus. However, we did observe significant gene-gene interactions. The APOE genotype had statistically significant epistatic effects with rs2638363 and rs12721331 for the right hippocampus volume over time ( Table 2) . In both cases, the presence of both the risk AGTR1 allele and the APOE4 allele was associated with accelerated hippocampal volume loss. We observed a similar trend that did not achieve statistical significance for the interaction between rs1492103, APOE, and time ( Table 2) . 
Longitudinal Effects of AGTR1 SNPs on Composite Cognitive Measures
We next tested whether AGTR1 variants confer risk for cognitive decline. A total of 138 elderly participants (63 depressed and 75 nondepressed) had both genotype and neurocognitive assessment data and were included in these analyses. This sample partially overlaps with the sample examining hippocampal volumes, with 81 participants (36 depressed and 45 nondepressed) included in both analyses. As expected, depressed individuals performed significantly worse than nondepressed individuals on univariate comparisons of the four composite cognitive measures of episodic memory (t=5.14, df=106, p,0.0001), executive speed (t=4.36, df=67, p,0.0001), verbal fluency (t=5.18, df=136, p,0.0001), and working memory (t=2.97, df=114, p=0.0037).
We used mixed models to examine the effect of AGTR1 genotypes and their interaction with time on each of the composite cognitive measures. All models controlled for diagnosis (depressed or nondepressed), age, sex, education, time, and baseline cognitive measure score. In these models, only rs2638363 displayed a significant main effect of genotype on composite episodic memory performance (F=4.59, df=1, 126, p=0.0340), but the genotype-by-time interaction did not reach significance. Similarly, rs1492103 exhibited a trend for a direct effect on episodic memory (F=3.85, df=1, 126, p=0.0519), but this did not reach statistical significance. Finally, rs2675511 exhibited a gene-bytime interaction (F=5.61, df=1, 125, p=0.0194) predicting worsening episodic memory performance. In accordance with SNP effects on hippocampal volumes, individuals homozygous for the vascular risk alleles (rs2638363 GG, rs1492103 TT, and rs2675511 AA) exhibited lower episodic memory scores. None of the four genetic variants exhibited either a statistically significant direct effect or interaction with time effect on executive speed, verbal fluency, or working memory.
Discussion
Replicating and extending our previous findings of AGTR1 effects on right hippocampal morphology (14) , three of the same SNPs predicted longitudinal hippocampal volume change in the right but not the left hemisphere in elderly individuals. The direction of the observed relationships was similar to results from the previous crosssectional study, that is, each of the previously identified "risk" genotypes (rs2638363 GG, rs1492103 TT, and rs2675511 AA) predicted longitudinally greater shrinkage of the right hippocampus when compared with the alternate genotypes. Intriguingly, these AGTR1 risk alleles also predicted poorer performance in episodic memory, a neurocognitive measure mediated by the hippocampus, but had no effects on other cognitive measures. Additionally, two risk variants (rs2638363 and rs12721331) showed epistatic effects with the APOE4 allele, a known risk factor for dementia (26) , on right hippocampal volume loss over time. Importantly, the SNPs examined are in low pairwise linkage disequilibrium (r 2 ,0.5) and thus represent independent signals. The presence of several signals within the AGTR1 locus that are independently associated with hippocampal volume changes and memory decline lends further support to the reliability of these associations. Taken together, our findings strongly support that AGTR1 gene variants may confer vulnerability via both direct and epistatic effects for progressive memory decline by accelerating hippocampal volume loss. The main findings and the supported model are schematically summarized in Figure 1 .
Our study offers novel insights into the role of the reninangiotensin system (RAS) in hippocampal atrophy and cognitive decline. Hippocampal atrophy has been shown to predict cognitive decline in late life and time-to-conversion to Alzheimer's disease (5, 30) . Previous animal and human studies support involvement of the RAS in cognitive syndromes AJP in Advance ajp.psychiatryonline.org (6, 14, 31) . RAS activation modulates cerebral blood flow, increases brain vulnerability to ischemia, and promotes brain inflammation (6, 32) . These effects render this system particularly relevant in late life, where vascular and inflammatory processes are hypothesized to contribute to depressive and cognitive syndromes (10, 33) . On the other hand, AT 1 receptor blockade dampens stress responses, ameliorates anxious and depressive behaviors, and reduces brain inflammation and vulnerability to ischemia (6, 8, 32) . Thus, it is plausible that perturbations in the RAS could heighten the risk for developing dementia by accelerating age-related changes in brain morphology, particularly in brain regions most vulnerable to the effects of aging, such as the hippocampus. Although RAS activity may be modulated by functional variants at the AGTR1 locus, the molecular effects of the risk AGTR1 SNPs are currently not clear. Despite their intronic location, these SNPs could have functional effects. For instance, intronic SNPs may be located in enhancer regions that influence the three-dimensional changes in chromatin conformation necessary for transcription regulation (34) . Alternately, these SNPs may be tagging other functional variants in nearby regions of the AGTR1 locus. Finally, as supported by the epistatic effects with APOE observed in our study, these SNPs may have functional effects via interaction with other genes that lie in common biological pathways central for the development of brain pathology and dementia. Future studies on the functional effects of these genetic variants are warranted and may shed light on the mechanisms linking AGTR1 and cognitive syndromes. Intriguingly, the effects of AGTR1 variation were lateralized to the right hippocampus, which is in accordance with our previous cross-sectional study (14) . Although the significance of this lateralization is unclear, hippocampal asymmetry may be an important endophenotype that has been underemphasized by previous studies. Hippocampal asymmetry has been observed in patients with severe depression and in nondepressed relatives of depressed individuals (35, 36) . Furthermore, unilateral hippocampal volume changes may be associated with decline in specific cognitive outcomes (5, 37) and with decreased likelihood of achieving antidepressant remission (4). Thus, hippocampal asymmetry may be an early step in the pathogenesis of some late-life mood and cognitive syndromes. This asymmetry could be induced by differential hemispheric effects of the RAS on the hippocampus. Notably, activity of angiotensinase, an enzyme that metabolizes angiotensin, has been found to be distributed asymmetrically between the left and right hippocampi of the rat brain (38, 39) . This may also reflect differential activity of angiotensin and Table 2 .
potentially asymmetric effects of AGTR1 genetic variants between the two hemispheres. Whether this mechanism holds true, and the clinical significance of these asymmetries, remains to be determined. Several limitations should be considered when interpreting our findings. Although we controlled for the effects of depression diagnosis and basic demographic factors on hippocampal morphology, we did not control for antidepressant treatments that may have neurotrophic effects on the hippocampus (40) and may even reverse hippocampal volume loss in some cases of depression (37) . Depressed participants were treated based on an algorithm rather than a rigid clinical trial. Although this makes our approach comparable to clinical practice, it makes it challenging to elucidate the effects of antidepressants. Data on antidepressant use prior to enrollment, as well as specific treatment modalities, duration, and dosages used over the study period, were not known for each participant. Thus, it is possible that variable treatments between genotype groups may have influenced our results. However, the assignment of treatment modalities occurred randomly and treating clinicians were blind to genotype groups, and thus systematic errors cannot account for our findings. Another limitation was our focus on variation at a single genetic locus and a single brain region. This was based on our sample size and the a priori plausible involvement of AGTR1 and hippocampal pathology in late-life neuropsychiatric syndromes. Larger longitudinal studies are warranted for a more systematic examination of the multiple brain regions, genes, and biological pathways involved in the pathogenesis of these syndromes. Our study shows that the RAS is one such pathway that should be included in future pathogenetic models.
In summary, this is the first study to our knowledge to explore the longitudinal effects of AGTR1 genetic variation on hippocampal morphology and cognitive decline. In contrast with cross-sectional approaches that cannot establish temporal relationships, the present study reveals that older adults homozygous for AGTR1 risk variants exhibit accelerated hippocampal volume loss and memory decline. Our study exemplifies how examining the longitudinal effects of biologically plausible genotypes on relevant endophenotypes may provide novel insights into the pathogenesis of complex phenotypes. It further suggests that molecules involved in the RAS may serve as early therapeutic targets for late-life neuropsychiatric syndromes. 
Background
There is a need to identify early biomarkers indicative of Alzheimer's disease risk as the presentation of clinically evident symptoms lag behind the development of neuropathology (Jack et al. 2013, Risacher and Saykin 2013) . Supporting this goal, it is important to understand how genetic differences that increase Alzheimer's disease risk may influence cognitive performance and brain structure in pre-clinical populations. This is particularly relevant to younger adult populations who could benefit from preventive strategies. When considering genotypic effects, it is important to test not only for direct relationships but also whether genetic influences alter the effect of age on clinical or imaging measures. Similarly, it is important to examine interactive effects of common conditions that are themselves associated with an increased risk of dementia, such as depression (Byers et al. 2012) . Apolipoprotein E (apoE) is a very-low-density lipoprotein involved in transporting cholesterol from the blood. In the central nervous system, the apoE lipoprotein is involved in mobilization of cholesterol and fatty acids, aids in recovery from injury and promotes synaptic plasticity (Mahley and Huang 2012; Nathan et al. 1994 ). The human APOE gene coding for this protein is located on chromosome 19 and has Preliminary data were previously presented at the 53rd Annual Meeting of the American College of Neuropsychopharmacology.
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3 allelic variants: ε2, ε3, and ε4. A large body of work demonstrates that the APOE ε4 allele is the primary genetic risk factor for the development of Alzheimer's disease in later life (Corder et al. 1993 ) and, compared with non-carriers, even healthy older ε4 carriers exhibit differences on cognitive testing (Caselli et al. 2004) . Similarly, healthy older ε4 carriers exhibit smaller volumes and greater rates of atrophy in multiple cortical and subcortical regions (Donix et ). Such differences may be reconciled by observations that the ε4 allele may be associated with regionally different effects, as a study examining gray matter networks in younger carriers found the ε4 allele was associated with gray matter reductions in frontal and cingulate regions, but relative increases in other regions including the hippocampus (Alexander et al. 2012) .
Just as aging is a risk factor for developing Alzheimer's disease, so is depression (Byers et al. 2012 , Diniz et al. 2013 . Depression increases the risk of dementia even occurring over a decade before dementia onset, although the effect of earlier life depression is primarily in APOE ε4 carriers (Karlsson et al. 2015) . Early work concluded that APOE genotype is not a risk factor for depression , but recent longitudinal population-based studies found that the ε4 allele was associated with prospectively identified depressive symptoms (Skoog et al. 2015 ). Studies in depressed older populations report that ε4 carriers exhibit greater depression severity, poorer cognitive performance, and smaller frontotemporal volumes (Corsentino et 
The purpose of the study was to examine influences of APOE genotype on cognition and gray matter structure in a young to midlife adult sample. Given the nature of the relationships between APOE ε4 genotype and pathological aging, we hypothesized we would observe an interactive effect between APOE genotype and age on cognition and brain structure. We also sought to determine whether APOE genotype's effects on cognition and brain structure differs in individuals with current major depressive disorder.
Methods Participants
Participants between the ages of 20 and 50 years were enrolled at Duke University and Vanderbilt University. Depressed participants had a DSM-IV diagnosis of recurrent MDD, as assessed by the Mini-International Neuropsychiatric Interview (MINI, version 5.0) (Sheehan et al. 1998 ) and interview with a study psychiatrist. Additional entry criteria included onset of first depressive episode before age 35 years and a Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg 1979) of 15 or greater. Entry criteria specified no antidepressant use in the last month; however, most subjects reported no antidepressant use for at least three months or longer. Eligible control subjects had neither any lifetime history of psychiatric disorders nor any history of psychotropic medication use.
Exclusion criteria included other lifetime DSM-IV Axis I disorders including substance abuse or dependence. Subjects were excluded for Axis II disorders determined by the Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) (First et al. 1997 ).
Brain Imaging and Behavior
Additional exclusion criteria included: history of psychosis, acute suicidality, use of illicit substances in the last month, ECT in the last 6 months, a family history of bipolar disorder, any unstable medical condition, any history of neurological illness or head injury, or MRI contraindications.
Both the Duke University Medical Center Institutional Review Board and the Vanderbilt University Institutional Review Board approved this study. All study participants provided informed consent. 
Neuropsychological testing
Participants completed a battery of neuropsychological tests that covered cognitive domains relevant to depression. A trained psychometric technician supervised by a licensed clinical psychologist administered neuropsychological testing. Similar to our past approach in late-life depression (Sheline et al. 2010), we created rationally constructed composite domain variables from a broad test battery. To combine tasks, we created Z-scores for each measure based on the performance of all participants and averaged the Z-scores for all tests within each domain for each individual. Internal consistency for each domain
MRI acquisition
To simplify data analyses across two sites using different MRI scanners by different manufacturers, only subjects with MRI data acquired at Duke University was included in these analyses. Cranial MRI was performed using the eight-channel parallel imaging head coil on a whole-body MRI system (Trio, Siemens Medical Systems, Malvern, PA). Parallel imaging was employed with an acceleration factor of 2. Duplicate T1-weighted image sets were acquired during the scan session using a sagittal MPRAGE sequence with TR/ TE = 2300/3.46 msec, a 240 Hz/pixel bandwidth, a 256 × 256 matrix, a 240 mm diameter field-of-view, 160 slices with a 1.2 mm slice thickness, yielding an image with voxel sizes of 0.9 × 0.9 × 1.2 mm.
Analyses of volumetric and cortical thickness MRI data
All volumetric measures were calculated using FreeSurfer (version 5
We also tested for differences in cortical thickness using Freesurfer's QDEC module. This was an atheoretical approach to test for differences not captured in atlas-based comparisons. In this method, cortical thickness is computed as the shortest distance between any point on the pial surface and the gray/white boundary and vice-versa; these two values are averaged (Fischl and Dale 2000) . Maps were smoothed using the standard Gaussian kernel of 10 mm. We used a general linear model (GLM) to test for differences in cortical thickness while correcting for multiple comparisons using the Monte Carlo simulation method. Data were tested against an empirical null distribution of maximum cluster size by running 10,000 synthesized Gaussian noise simulations with an initial threshold of p < 0.01. Right and left hemispheres were tested separately.
Selection of a priori regions of interest
Selection of a priori volumetric regions for primary analyses was based on work that identified APOE genotype effects on regional volumes. These included: the amygdala, hippocampus, entorhinal cortex, parahippocampal gyrus, precuneus, and cingulate cortex (Donix et For the cingulate cortex, we examined anterior divisions due to its implication in depression (Pizzagalli 2011 ) and posterior divisions due to APOE genotype's influence on metabolism in midlife populations (Protas et al. 2013 ).
Genotyping
Genotyping was conducted on blood samples. APOE alleles (corresponding to allele combinations at single nucleotide Brain Imaging and Behavior polymorphism (SNP) +3937/rs429358 and SNP + 4075/ rs7412) were genotyped using the ABI 7900 TaqMan (Applied Biosystems, Foster City, California, USA) system. The two APOE single nucleotide polymorphisms exist at amino acid 112 and 158, which are targeted by the TaqMan probes. The individual genotypes at the two sites are then combined to create a single standard APOE genotype.
Analytic plan
Our a priori hypotheses involved interactive effects between APOE ε4 genotype, age, and depression diagnosis, so we took a stepwise approach. All analyses were conducted with SAS 9.4 (Cary, NC) using PROC MIXED. Our primary analyses included all participants regardless of APOE genotype, however as the APOE ε2 allele may have protective effects (Suri et al. 2013) we also conducted follow-up analyses where ε2 carriers were excluded.
First, we created initial models that did not include interaction terms but instead tested for a direct effect of APOE ε4 genotype. In these models, either cognitive domain z-scores or MRI measures were the dependent variable, with APOE ε4 genotype (presence or absence of an ε4 allele), diagnosis (depressed/never depressed), age, sex, and race (white or minority). Analyses of cognitive data included the additional covariate of years of education, while analyses of imaging data included total intracranial volume and hemisphere. After testing for initial effects, we subsequently created additional models that included either an APOE by age interaction term or an APOE by diagnosis interaction term. Final models tested for a three-way age by APOE by depression diagnosis interaction.
For analyses of cognition, we focused on our a priori plan of examining the z-transformed summary measures of processing speed, working memory, episodic memory, and executive function. For domains with a statistically significant genotype effect or interaction term, we planned for subsequent analyses that would examine the individual z-transformed tests within those domains.
For analyses of volumetric MRI data, we initially focused on our a priori regions as described above. Subsequent analyses also considered other brain regions not specified in our a priori hypotheses but quantified by our image analysis method. Given the large number of regions identified, for analyses of regions not included in our a priori hypotheses we corrected for multiple comparisons using the false discovery rate (FDR) method. When testing for differences in cortical thickness using FreeSurfer's QDEC module, we used a general linear model (GLM) to test for differences between genotype groups, including age as an additional independent variable. This allowed us to examine the direct effects of APOE genotype on cortical thickness as well as test for statistical interactions between genotype and age.
To elucidate the relationship between cognition and structure, we examined cognitive domains and brain regions identified as exhibiting statistically significant relationship in the above planned analyses. In these analyses, we examined the ztransformed cognitive domain score as the dependent variable. Independent variables included age, sex, diagnosis, race, and education. We also included brain regions as independent variables, utilizing the mean volume across the hemispheres, normalized for total intracranial volume.
Results
APOE genotype effects on cognitive performance
The sample for cognitive analyses included participants recruited at both the Duke and Vanderbilt sites. This consisted of 107 APOE ε4 negative individual (48 % depressed, N = 51) and 50 APOE ε4 positive individuals (42 % depressed, N = 21; Table 1 ). There was no significant difference in APOE ε4 frequency between diagnostic groups (χ 2 = 0.44, p = 0.5070). The complete genotypic breakdown consisted of: 2/2, N = 2; 2/3, N = 14; 2/4, N = 4; 3/3, N = 87; 3/4, N = 45; 4/4, N = 5). The depressed cohort was significantly older and exhibited greater severity of depressive symptoms by MADRS than the nondepressed cohort, but there was no significant difference in age or MADRS score within each diagnostic cohort between those who were and were not ε4 carriers. After controlling for demographic covariates, we did not observe any statistically significant differences in the ztransformed cognitive domain scores between individuals identified by both genotype and diagnosis (Table 1) .
In primary models without interaction terms, we did not find direct effects of either APOE genotype or diagnosis on any cognitive domain score. We also did not observe any statistically significant interactions between depression diagnosis and genotype on cognitive domain scores. Similarly, we did not find statistically significant three-way interactions between APOE genotype, age, and depression.
On testing for an interaction between age and APOE genotype, we found a significant interaction for executive function (F 1,149 = 4.23, p = 0.0415) and a trend for episodic memory (F 1,149 = 3.16, p = 0.0779) but no difference for other domains (working memory: F 1,149 = 1.90, p = 0.1707; processing speed: F 1,149 = 0.01, p = 0.9038). In analysis of executive function, APOE ε4 noncarriers exhibited worse executive function with increasing age than did the ε4 carriers (Fig. 1) . In other words, presence of the APOE ε4 allele reduced the effect of age on executive function.
We conducted additional analyses for the executive function and episodic memory domains, examining the ztransformed individual test items included in the composite domain scores. Controlling for the same covariates as in The interactions were similar to those observed with the executive function composite score, where ε4 carriers exhibited less reduction in performance with age ( Fig. 1) . In the absence of the age by genotype interaction term, APOE genotype did not have a direct effect on test measures.
Secondary analyses where we excluded the twenty ε2 carriers were largely concordant with the results described above. We continued to observe a significant interaction between age There was no difference in APOE ε4 frequency between depressed and nondepressed groups in the MRI sample (ε4 -, MDD N = 41; ε4 -, no MDD N = 47; ε4 +, MDD N = 17; ε4 +, no MDD N = 26; χ 2 = 0.58, p = 0.4452). Other demographic comparisons were comparable to the larger sample (Supplemental Table 1 ).
In primary models examining a priori defined regional brain volumes, we did not find direct effects of either APOE genotype or depression diagnosis on any region. We also did not observe any statistically significant interactions between depression diagnosis and genotype on regional volumes. Similarly, we did not find statistically significant three-way interactions between APOE genotype, age, and depression.
In analyses of our a priori defined regions, we observed statistically significant interactions between APOE genotype and age for the entorhinal cortex, rostral and caudal cingulate cortex (Table 2) . Similar to what is observed in the cognitive analyses, the APOE ε4 allele reduced the effect of age on regional volumes (Fig. 2) . In other words, the relationship between age and volume exhibits a more negative slope in APOE ε4 noncarriers compared with ε4 carriers. These findings persisted when removing the seventeen APOE ε2 allele carriers, and we additionally observed an interaction between age and genotype for the parahippocampal gyrus.
Additional analyses examined other regions measured by FreeSurfer that were not part of our a priori hypotheses, where we again created similar models testing for direct and interactive effects of APOE genotype. After FDR correction for multiple comparisons, we observed neither statistically significant primary effects nor interactive effects of APOE genotype.
APOE genotype effects on cortical thickness
We found no statistically significant effects where APOE genotype was directly associated with differences in cortical thickness. When examining age by genotype interactions, we did not observe any regions where the effect of age on cortical thickness differed significantly between the APOE genotype groups. Similarly, we observed no differences when testing for different effects of genotype between depressed and nondepressed participants.
Relationship between cognitive domains and regional brain volumes
Finally we sought to examine the relationship between cognitive domains and regional volumes identified in the above analyses. These analyses focused on the z-transformed executive function domain score, examining the entorhinal cortex, parahippocampal gyrus, and caudal and rostral anterior cingulate cortex volumes. After controlling for demographic differences, normalized parahippocamapal gyrus (F 1,124 = 7.66, p = 0.0065) and rostral anterior cingulate cortex volumes (F 1,124 = 6.18, p = 0.0143) were significantly associated with executive function. There was also a trend for the caudal anterior cingulate cortex volume (F 1,124 = 3.86, p = 0.0518) but no relationship with entorhinal cortex volume (F 1,124 = 2.06, p = 0.1536).
Discussion
Our major finding is that in a younger adult population, the APOE ε4 allele reduces the effect of aging on executive function and regional brain volumes in temporal and anterior cingulate regions. Overall APOE ε4 carriers exhibited less reduction in executive function and regional volumes with age than did APOE ε4 noncarriers. We did not observe a direct effect of APOE genotype on cognition or brain morphology. We also did not find evidence to support that depression diagnosis interacted with APOE genotype to result in greater deficits in cognition or altered brain morphology. These findings were persistent across the entire sample, then also when we limited the sample to individuals who did not carry the ε2 allele.
Integration with aging literature
Our analyses of APOE genotype's effect in younger adults are concordant with and extend past work. These findings support the theory of antagonistic pleiotropy (Han and Bondi 2008) , or that the ε4 allele has different effects on cognition at different ages. This may represent superior compensatory function during midlife. Had our sample's age extended past age 50 years, we anticipate that we would observe a downward curve in the age-cognition relationship in older ε4 carriers.
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Recent work suggests this more rapid rate of cognitive decline in ε4 carriers occurs around age 70 years (Jack et al. 2015) , well beyond our current sample.
There is still uncertainty about what cognitive domains may be differentially affected by APOE genotype. We found that genotype influenced the effect of age in our executive function domain (specifically performance on the Trails B and COWA) and visual memory measured with the BVRT. These findings are supported by past studies (Marchant et al. 2010 ), although APOE effects on attention ) may also be influencing performance on our executive function tests.
Our neuroimaging findings follow a pattern similar to our cognitive findings. These results are discrepant with a previous study that did not observe interactive effects of APOE genotype and age on structural measures (Filippini et al. 2011 ). However, that study examined a smaller sample with two distinct age populations rather than a young to midlife adult sample with a continuous age range.
This work supports that aging is associated with poorer cognitive performance and smaller brain volumes, even in young to midlife adults. Our observations occur before ages where significant increases in amyloidosis occur (Jack et al. 2015) and such aging effects are reduced in APOE ε4 carriers. Brain aging in younger adults may be due to multiple causes, including vascular risk factors, early tauopathy (Crary et al. 2014 , Jack et al. 2013 ), or occur in the absence of any specific pathology (Jagust 2013 ). Further work is needed to better understand what processes are modified in APOE ε4 allele carriers and how that benefit to cognition and brain structure is obtained prior to later amyloid deposition and cognitive decline.
Integration with depression literature
It is clear that neuropathology related to cognitive decline can occur decades before the onset of clinical symptoms (Jack et al. 2013 ) and that earlier-life onset is associated with increased dementia risk (Byers et al. 2012 ). However, there are few studies examining the relationship between depression and risk factors for Alzheimer's disease in younger adult populations. We observed neither differential effects of APOE genotype nor different genotype by age interactions between depressed and nondepressed individuals. This does not support a theory that cognitive or morphological differences related to APOE genotype may adversely affect neural circuitry in such a way that it would increase a predisposition to depression. Overall this suggests that the ultimate pathways by which depression increases dementia risk does not occur through apolipoprotein E mediated mechanisms in younger adults. However, the underlying nature of the relationship between depression and dementia remains an important question and alternative pathways should be considered, such as the relationship between depression and proinflammatory processes.
Study strengths and limitations
The study has several strengths, including a large sample size and comprehensive neuropsychological testing battery. Moreover image analyses utilized a combination of hypothesis-testing and hypothesis-generating approaches. These methods are complementary, as we found no relationship between study measures and cortical thickness, but did find volumetric differences in cingulate cortex regions and subcortical structures. Finally, in post-hoc analyses, we demonstrated a relationship between the identified cognitive domain (executive function) and identified brain regions (parahippocampal gyrus and rostral anterior cingulate cortex).
The study also has limitations. Although we have a broad cognitive battery, specific domains such as attention (Rusted ) were not assessed. Additionally, this was a welleducated sample and it is unclear if these results would generalize to populations with lower education. Moreover, although we examine age effects, this remains a crosssectional study. Ultimately longitudinal studies are necessary to examine change in such measures and aging trajectories. Finally, there are notable limitations related to the sample, including a lower number of APOE ε4 allele carriers than ε4 noncarriers, although this limitation applies to much of the existent literature. The age difference between the diagnostic cohorts is also important. The strong effect of age on both cognitive and brain aging may have negatively affected our ability to detect a diagnosis by genotype interaction. It should be emphasized that despite examining a relatively large sample, we made numerous statistical comparisons. For our a priori hypotheses, we did not control for multiple comparisons, thus increasing the risk for a type 1 error. Given the significance levels observed, correcting for multiple comparisons would have resulted in null findings. Thus while our findings fit within past literature, they should be viewed cautiously.
Despite these limitations, this study advances our understanding of the aging process by demonstrating that the APOE ε4 allele mitigates the effect of age on cognitive processes and brain structure in early-to midlifeadulthood. This occurs prior to significant increases in amyloid deposition as detected by PET scanning (Jack et al. 2015) , suggesting that the ε4 allele may modify other processes influencing brain aging. More work is needed to determine what those processes are, but also to determine how depression may increase risk of dementia. Fig. 2 Differences in age effects on regional brain volumes between APOE ε4 positive and negative individuals. Data presented are those regions exhibiting statistically significant age by genotype interactive effects on regional volumes, after controlling for depression diagnosis, sex, race, intracranial volume and hemisphere. Similar findings were observed unilaterally for the hippocampus, parahippocampus, and amygdala (figures not shown). APOE ε4 noncarriers are triangles/solid line, APOE ε4 carriers are squares/dashed line. Ztransformed test performance score on the y-axis, age in years on x-axis. Regional volume in milliliters on the y-axis, age in years on x-axis
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WMHs in LLD LLD is consistently associated with greater WMH severity [25] [26] [27] [28] and greater measured WMH volumes. 10, [29] [30] [31] These observations guided proposals for MRI-defined vascular depression diagnostic criteria that include a lesion severity criterion. 32, 33 In such conceptualizations, age at the initial depressive episode is an important consideration. Compared with early-onset depression, individuals with a later onset (for example, after 50 years) exhibit greater WMH severity 5, 18, 31, [34] [35] [36] [37] [38] and cognitive impairment. 39, 40 However, 'vascular depression' as a potential diagnostic entity may not be limited to late-onset patients. Individuals with an earlier onset are at increased vascular risk, as precedent depression is associated with increased risk of vascular disease and stroke. [41] [42] [43] [44] [45] Depression in early and midlife may promote inflammation [46] [47] [48] or epigenetic modifications of genes related to vascular homeostasis. 49 Thus, some individuals with early-onset depression may be prone to 'vascular depression' later in life.
Localization of WMHs
Although many studies do not specify lesion location, distinctions in WMH location are important in understanding their role in LLD. In nondepressed samples, periventricular WMHs are more closely associated with cognitive impairment than are deep WMHs. [50] [51] [52] It is possible that this is due to anatomical differences, as the periventricular region has a high density of long associating fibers with cortical-subcortical connections, whereas subcortical deep white matter has a high density of shorter U-fibers connecting adjacent cortical regions. 52, 53 However, as WMH severity across regions is highly correlated, distinctions between periventricular and deep WMH may be arbitrary and reflect total WMH disease. 54 Nonetheless, others have localized WMHs associated with depression to the frontal [55] [56] [57] [58] and temporal lobe. 59 More recently several groups reported that LLD is associated with greater WMH severity in specific white matter fiber tracts, including the cingulum bundle, uncinate fasciculus and superior longitudinal fasciculus. [60] [61] [62] WMHs and cerebral function A small number of studies suggest that greater WMH burden is associated with disrupted function in motor, cognitive and affective circuits. During a simple motor task, high WMH burden is associated with low BOLD functional signal, 63 suggesting that WMH disease interferes with the neural circuit mediating the task. Other studies 64, 65 associated low BOLD activity with poorer performance on executive tasks, supporting the model of altered white matter integrity leading to cognitive network dysfunction. Greater WMH volume is further associated with altered default mode network connectivity at rest between the posterior cingulate cortex and medial prefrontal cortex (PFC). 66 During affective tasks in LLD, WMHs are associated with altered functional activity with an exaggeration of the functional 'depression' fMRI patterns: individuals with high WMH burden showed hyperactivation in limbic regions when presented with fearful faces. 67 Neuropathological studies Studies utilizing both neuroimaging and neuropathological techniques demonstrate that WMHs represent a wide range of pathological processes, including perivascular demyelination, arteriosclerosis, ischemia, gliosis, or partial loss of myelin and axons. 15, 68, 69 Generally, confluent deep WMH but not periventricular WMH appear to be related to ischemic processes. 70 There are also regional differences in WMH etiology. Seminal work by Thomas and colleagues 14 showed that deep WMH and punctate lesions of depressed older adults are most likely to have ischemic origins. In LLD ischemic lesions are also more likely to occur in the dorsolateral prefrontal cortex, instead of the anterior cingulate cortex or occipital lobe. Similarly, depressed elders exhibit increased expression of cellular adhesion molecules in the dorsolateral prefrontal cortex, but not the anterior cingulate cortex or occipital lobe. [71] [72] [73] Cellular adhesion molecules are inflammatory markers whose expression is increased by ischemia, supporting a role for ischemia in LLD and highlighting the relationship between vascular and inflammatory processes. Although ischemic pathology is thus consistently localized to the dorsolateral prefrontal cortex, other frontal regions may also be involved. Depressed elders exhibit decreased density of pyramidal neurons in the orbitofrontal cortex, which may be the result of vascular processes 74 in arterioles and medium arteries, 75 or alterations in astrocyte-associated immune function.
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Neuropathological studies also demonstrate that LLD can develop in the absence of significant vascular abnormalities. In a study of late-onset depressed elders, depression was not related to either lacunes or microvascular lesions. 77 Similarly, in a population-based study in which depression was ascertained in a pre-mortem diagnostic interview, depression was associated neither with cerebrovascular nor Alzheimer pathology. 78 However, in contrast to prior studies, 79 depression was associated with the presence of Lewy bodies. 78 Such findings highlight the heterogeneity of pathologies that present as depression.
THE DEPRESSION-EXECUTIVE DYSFUNCTION SYNDROME AND COGNITIVE DEFICITS IN LLD
A 'depression-executive dysfunction syndrome' 4 was conceptualized as the clinical expression of frontal network impairment caused by vascular and other age-related factors. Accordingly, this syndrome describes depressed patients with vascular disease and evidence of impairment in networks related to mood and executive function. 80 Executive function is a frontally mediated domain [81] [82] [83] that encompasses cognitive processes including selective attention, response inhibition and performance monitoring. It is clinically expressed as difficulty with planning, sequencing, organizing and abstracting. These deficits are common in LLD, [84] [85] [86] [87] particularly in late-onset depression. 40, 86, 88 Efforts to characterize the presentation of the depression-executive dysfunction syndrome have dichotomized samples by their performance on executive function tasks. When compared with depressed elders without executive dysfunction, patients with depression-executive dysfunction exhibit reduced fluency, impaired visual naming, suspiciousness, anhedonia, psychomotor retardation and significant disability. [89] [90] [91] As discussed later, studies across eight different samples identified executive dysfunction as a predictor of poor antidepressant response. [92] [93] [94] [95] [96] [97] [98] [99] Broader cognitive deficits in LLD: relationship with vascular risk factors Individuals with LLD exhibit executive dysfunction and deficits across other cognitive domains, including episodic memory, working memory, visuospatial ability and processing speed. 84, 87, [100] [101] [102] [103] [104] [105] Processing speed deficits may influence other cognitive deficits [103] [104] [105] and mediate in part executive task performance. 106 Although cognitive performance improves with successful antidepressant treatment, such deficits can persist and performance may not be restored to a normal level. 100, [107] [108] [109] Cognitive deficits are associated with vascular dysfunction. In nondepressed cohorts, there are associations between episodic memory, psychomotor speed and executive function, and measures of vascular dysfunction, such as hypertension, heart rate variability and orthostasis. [110] [111] [112] In LLD, Framingham Vascular Risk scores 113 are associated with deficits in processing speed, executive function and episodic memory. 98, 104 Greater WMH burden is associated not only with executive dysfunction, perseveration and slowed processing speed 12, 61, [114] [115] [116] [117] but also with episodic and visuospatial memory deficits. 102, 110, 118, 119 These cross-sectional observations are supported by longitudinal studies, demonstrating that progression of WMH severity parallels cognitive decline. [120] [121] [122] WMHs localized to specific fiber tracts are associated with specific cognitive deficits. Executive function deficits are associated with WMHs in the uncinate fasciculus, superior longitudinal fasciculus and the cingulum bundle. 123 Similarly, episodic memory deficits are associated with WMHs in the cingulum bundle and inferior longitudinal fasciculus. 123, 124 VASCULAR DEPRESSION AND COURSE OF DEPRESSION Cognitive dysfunction and antidepressant outcomes In LLD, the relationship between treatment outcome and executive dysfunction is well established. Multiple studies demonstrate that executive dysfunction predicts poor acute response of LLD to antidepressants. 92, 94, 96, 97, 99, 125 Executive dysfunction is also associated with high relapse and recurrence rates, 126 although not all studies found this association. 127 Much of this work used the Mattis Dementia Rating Scale InitiationPerseveration (I/P) subtest, which yields a composite score of several executive skills. 128 Notably, a recent meta-analysis examined the relationship between antidepressant response and performance across multiple executive tests, including the I/P subtest, the Wisconsin Card Sort Test, the Stroop Color-Word test and others. The authors concluded that the I/P subtest was the only test providing reliable discrimination between antidepressant responders and nonresponders. 129 Further analysis of I/P subtest components showed that semantic strategy (semantic clustering) while performing the I/P verbal fluency task explained most of the variance in predicting remission. 130 Effective semantic strategy appears to be associated with treatment response regardless of the probing task; effective semantic strategy during verbal learning task was also associated with high LLD remission rate. 131 These observations suggest that preserved semantic organization, rather than fluency or verbal learning, is critical for remission during antidepressant treatment. However, impaired response inhibition is another aspect of executive dysfunction that influences antidepressant response. 92, 95, 125, 132 Corroborating the role of the cognitive control network in LLD are reports examining resting state functional connectivity (FC). Low-resting FC in the cognitive control network, but not in the default network, predict poor, acute antidepressant remission rates along with persistence of depression, apathy and dysexecutive behavior. 133 Other cognitive deficits can influence outcomes. Poorer performance on tests of episodic memory, language processing and processing speed are associated with poorer acute antidepressant response, 98 and may predict poorer long-term course of depression. 134 Further analysis is needed to identify a superordinate cognitive dysfunction that accounts for the relationship of these tests to antidepressant response.
WMHs as a predictor of antidepressant outcomes Although greater WMH severity is often associated with poorer acute antidepressant response, 36, 98, 99, [135] [136] [137] [138] results are inconsistent. 97, [139] [140] [141] [142] Importantly, these studies assess total cerebral WMH severity, while the effect of WMLs on the antidepressant response may depend on lesion location. 138 Unfortunately, methodological differences in assessing WMH severity make it difficult to reconcile discrepant findings across studies. 143, 144 Most studies used cross-sectional WMH measures to predict outcome. However, WMHs are a progressive rather than a static process, 11, 145 and rate of change may be a more important predictor. The few studies in LLD cohorts examining this question found that greater increases in WMH volume over 2-and 4-year intervals are associated with nonremission or relapse. 146, 147 Some have examined both WMH severity and cognitive dysfunction as predictors of outcome. In these studies cognitive measures are generally a better predictor of antidepressant response than are WMH measures. The largest published study examining a 12-week response to sertraline found that poorer response was independently associated with greater WMH severity and poorer performance in cognitive domains of episodic memory, language processing, processing speed and executive function. However, in models controlling for baseline depression severity, WMH severity was no longer associated with response. 98 Smaller studies have found similar patterns, wherein initial associations between WMH severity and response were not statistically significant in models incorporating cognitive measures. 97, 99 Other measures of white matter integrity are associated with antidepressant response. In voxel-wide analysis, microstructural white matter abnormalities (low fractional anisotropy, FA) in multiple frontolimbic brain areas, including the rostral and dorsal anterior cingulate, dorsolateral PFC, genu of the corpus callosum, hippocampus and posterior cingulate, were associated with nonremission. 148 In region of interest analyses, low FA in the corpus callosum, left superior corona radiata and right inferior longitudinal fasciculum, was associated with lower remission rates. 149 In contrast, others found that higher prefrontal white matter FA was associated with a failure to remit to antidepressants, 150 a finding that parallels reports in depression of increased FC to a dorsal nexus. 151 Notably, depressed elderly 5-HTTLPR polymorphism short allele carriers had lower FA than long allele homozygotes in frontolimbic areas, including the anterior cingulate, posterior cingulate, dorsolateral and medial prefrontal regions. 152 Such differences in FA can be caused by several pathologies, not all of which are vascular in nature.
VASCULAR RISK GENES IN DEPRESSION
There is a wide literature examining genetic influences in LLD, including reports examining polymorphisms in BDNF, APOE and serotonin transporter (5-HTTLPR) genes, among others (see recent reviews by Lotrich 153 and Benjamin and Taylor 154 ). Within this field, there are an increasing number of reports associating LLD with genetic polymorphisms, increasing vascular risk.
One example of this literature includes studies examining genetic variation of the renin-angiotensin system (RAS). The RAS regulates fluid homeostasis and blood pressure, and is a target for two classes of antihypertensive drugs. Beyond influencing vascular function, RAS polymorphisms may also increase the risk of depression via modulation of monoamines 155 or contributing to hypothalamic-pituitary-adrenal axis dysregulation. 156 Results from studies examining the common angiotensin-converting enzyme (ACE) insertion/deletion polymorphism are mixed in adult depression [157] [158] [159] [160] [161] [162] and suicidality, [162] [163] [164] although other ACE polymorphisms may be important. 161, 165, 166 Despite its key role in the RAS, the gene encoding for the angiotensin II type 1 receptor (AGTR1) is less well studied. The CC genotype of the A1166C (rs5186) polymorphism is associated with increased responsiveness to Ang-II. 167 However, despite one study associating the CC genotype with increased risk of major depressive disorder, 159 this was not replicated in an elderly sample. 168 RAS variation is further related to differences in brain structure and function. Several studies in older adults have now associated variants in ACE and AGTR1 with altered cerebral frontotemporal structure [169] [170] [171] [172] and abnormal default mode network activity.
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AGTR1 variants are associated with greater WMH progression, particularly in men, 168 and this effect may be localized to specific tracts. 60 RAS polymorphisms may also influence antidepressant outcomes. In a general adult population, the ACE D variant and the AGTR1 C1166 allele are associated with better acute antidepressant response. 174, 175 However, this contrasts with a study of LLD, wherein AGTR1 C1166 allele homozygous individuals exhibited a poorer antidepressant response over a longer period. 176 Such age differences could be important, reflecting stress reactivity in earlier life and allostatic effects of an overly active RAS later in life.
MECHANISTIC HYPOTHESES
According to a model by Alexopoulos, 1 the clinical expression of LLD is mediated by altered brain activity in cognitive and affective circuits, characterized as hypometabolism of dorsal cortical regions and hypermetabolism of ventral limbic structures. Age-, disease-and stress-related neurobiological changes serve as etiological factors, contributing to alterations in circuits regulating mood and cognition. The impact of these neurobiological contributors can be increased by vulnerability factors originating from preexisting differences in mood circuitry.
Arguably, such etiological factors may lead to depression only after crossing a certain threshold, above which they acquire a dose-effect relationship (Figure 1 ). In this conceptualization, single or multiple potential 'etiological factors' may reach an initial severity threshold and contribute to LLD 'vulnerability' due to frontolimbic compromise evident through imaging or abnormal performance on cognitive or affective tasks. When etiological factors further increase in severity and cross a second threshold, they may have a greater and direct effect on mood circuit function, leading to affective and cognitive symptomatology. Of course, instead of threshold effects such relationships could be cumulative following linear or curvilinear patterns. Such a threshold model can account for multifactorial contributions to LLD. It also explains why our best clinical and biological measures predict only a modest part of the variance in distinguishing LLD from controls and in predicting treatment response as any individual measure may itself not cross a crucial threshold. This model allows for mixed syndromes of multiple etiological contributors, if each disturbance alone or in combination is strong enough to cross the threshold required to induce neural circuit changes mediating LLD.
Given the central role of vascular disease and WMHs in much of the literature, it is worth examining their role within this model. WMHs can be conceptualized as visible markers of ischemic damage, although vascular compromise may result in insults to white and/or gray matter that are not visible on conventional neuroimaging. 177 In this context, greater WMH severity represents a state of vascular compromise and ischemic injury in specific regions. Depending on the severity of the underlying WMLs and how strongly they affect affective and cognitive circuitry, such damage may itself predispose individuals to depressive episodes. However, WMHs may also be an index of the severity of underlying vascular disease affecting neural circuits. In this case, the direct effect of WMHs on neural circuits may be modest compared with that of the underlying vascular process.
The disconnection hypothesis Building on the concept of 'disconnection syndromes,' ischemia and WMLs may contribute to depression by disrupting neural connections among regions regulating mood and cognition. 178 In this model, global cerebral WMH severity is less germane to LLD than is focal damage to specific fiber tracts and neural circuits. Such focal damage would adversely affect the tract's structural and functional connectivity. In turn, this state adversely affects the function of connected regions at rest and during cognitive tasks, and contribute to neural circuitry alterations that mediate clinical symptoms and influence antidepressant response. This view is supported by studies examining WMH location. Recent work demonstrates that LLD is associated with greater WMH severity in specific tracts including the cingulum bundle, uncinate fasciculus and superior longitudinal fasciculus. [60] [61] [62] In addition, greater WMH severity in the uncinate and superior longitudinal fasciculi is associated with executive dysfunction 61, 123, 124 and greater depression severity. 179 These macrostructural MR findings are supported by diffusion tensor imaging (DTI) studies, examining white matter microstructure. DTI changes reflect various pathologies leading to decreased myelin integrity, including demyelination secondary to cerebrovascular and inflammatory changes. WMLs occurring in fiber tracts are also associated with DTI changes. 177, 180 LLD is associated with differences on DTI measures of the uncinate fasciculus, cingulum bundle, anterior thalamic radiation and superior longitudinal fasciculus. 181, 182 The uncinate fasciculus and cingulum bundle are particularly relevant to LLD [183] [184] [185] [186] [187] [188] because of their role in cognition and emotion processing, 188, 189 although other tracts are also associated with antidepressant response in LLD. 149 Importantly, differences in the uncinate fasciculus and cingulum bundle are also observed in younger, depressed adults. 190, 191 Although those younger adult studies do not necessarily suggest a vascular cause in that population, they support that structural alterations in these fiber tracts are associated with depression.
Structural differences have functional effects. Fiber tract structural connectivity is positively correlated with resting state FC of connected regions. [192] [193] [194] [195] [196] These data warrant a comprehensive examination of the relationships among ischemic focal WML injury, damage to tract microstructure, regional connectivity and circuit function. Examination of such a 'lesion model' can identify neural circuit deficits contributing to depression and predictive of poor outcomes.
The inflammation hypothesis Aging-and disease-related processes promote proinflammatory states in older individuals. 197, 198 Further, immune activation can be a characteristic of depression 48, 199 and precipitate depressive symptoms. 200 Alexopoulos and Morimoto 201 recently proposed that immune dysregulation may promote the development of affective and cognitive symptoms in LLD. This view is supported by studies in midlife adult populations. Administration of cytokines or induction of peripheral inflammation results in an inflammatory response, which in turn is correlated with fatigue, slowed reaction time 202 and mood reduction. 200, 203 Even without medical illness, depressed individuals exhibit increased levels of Figure 1 . Proposed progression of etiological processes affecting frontolimbic function. After crossing an initial threshold, vascular or other processes may serve as one of many factors that increase vulnerability to depression through compromise of affective and cognitive brain circuits. As the underlying disease process progresses, its adverse effects on the affective and cognitive circuits would likewise increase, resulting in the circuit dysfunctions that characterize depression. proinflammatory cytokines 204, 205 and reduced anti-inflammatory cytokine levels. 206, 207 Several mechanisms may explain these relationships. Proinflammatory cytokines affect monoamine neurotransmitter pathways, 208 including indoleamine 2,3-dioxygenase upregulation and kynurenine pathway activation. [209] [210] [211] This results in decreased tryptophan and serotonin and increased synthesis of detrimental tryptophan catabolites that promote hippocampal damage and apoptosis. 211, 212 Cytokines, including interleukin (IL)-1b, also reduce extracellular serotonin levels by activating the serotonin transporter. 213 In addition, proinflammatory cytokines disrupt glucocorticoid receptor function 214 and reduce neurotrophic support. 215 Peripheral inflammation is associated with altered brain function in areas mediating cognition and mood. In healthy individuals, typhoid-induced IL-6 levels correlate with lower mood, increased subgenual anterior cingulate cortex activity during affective processing and altered subgenual cingulate connectivity. 203 Laboratory-administered social stressors increase inflammatory maker levels that in turn are associated with activation of the dorsal anterior cingulate cortex and anterior insula. 216 In bereaved women undergoing grief elicitation, inflammatory markers were positively associated with subgenual cingulate and orbitofrontal cortex activation. 217 Supporting this work is a growing literature demonstrating that genetic polymorphisms promoting proinflammatory processes may contribute to depression, 218, 219 and in LLD may be related to age of onset. 220 Such relationships are likely moderated through an effect on cytokine levels that in turn are associated with sad mood 221 and altered emotion processing. 222 Regarding LLD, the aging process disrupts immune function, 223 increasing peripheral immune activity and shifting the CNS into a proinflammatory state. 198 Elevated peripheral cytokine levels are associated with depressive symptoms in older adults, with the most consistent finding being for IL-6, but also implicating IL-1b, IL-8 and tumor necrosis factor-a. [224] [225] [226] [227] [228] Proinflammatory states in older adults are associated with cognitive deficits, including poorer executive function, poorer memory performance, worse global cognition and steeper decline in cognition. [229] [230] [231] Finally, greater IL-6 and C-reactive protein levels are associated with greater WMH burden. [232] [233] [234] [235] Successful antidepressant treatment may reduce proinflammatory markers. 48 This action may be a direct effect as in vitro studies demonstrate that antidepressants reduce proinflammatory markers while increasing levels of anti-inflammatory cytokines. [236] [237] [238] [239] [240] Results in clinical populations are inconsistent, but a recent meta-analysis concluded that antidepressants, particularly SSRIs, reduce IL-6, IL-1b and tumor necrosis factor-a. 241 Additional evidence supports that some anti-inflammatory drugs may have antidepressant properties, [242] [243] [244] particularly in individuals with elevated pretreatment proinflammatory markers. 245 Importantly, proinflammatory processes also contribute to neurodegenerative processes. Increased peripheral inflammatory marker levels are associated with increased risk for all-cause dementia, 246 and central inflammatory processes significantly contribute to the pathogenesis of Alzheimer's disease. 247 However, nonsteroidal anti-inflammatory drugs have not consistently demonstrated clinical benefit in Alzheimer's disease, 247 and in a recent consensus statement were considered but not recommended as a priority for further investigation. 248 The hypoperfusion hypothesis Vascular dysregulation is common in LLD [249] [250] [251] [252] [253] [254] and CBF reductions can impair regional brain function, contributing to affective and cognitive symptoms. Regional cerebral metabolic activity is tightly correlated with CBF, which is regulated by local interactions between neurons, glia and the vasculature. 255, 256 Blood flow to the brain is influenced by systemic hemodynamics and cerebrovascular autoregulation, with cerebral arteries contracting or dilating as arterial pressure changes. These processes interact to maintain stable perfusion. However, these processes are impaired in the context of vascular disease: 256 hypertension, diabetes and atherosclerosis leading to vascular wall hypertrophy, reduced arterial lumen diameter, reduced arterial distensibility and endothelial cell dysfunction. [256] [257] [258] Such vascular changes, including increased intima media thickness, increased arterial stiffness and endothelial dysfunction are pronounced in LLD populations, [249] [250] [251] [252] [253] [254] and endothelial function may be particularly poor in antidepressant nonresponders. 259 Such vascular pathology results in reduced blood flow velocities and decreased vasomotor reactivity, 260, 261 thus adversely affecting CBF. Perfusion deficits do not need to cause ischemia in order to influence brain function. Reduced CBF impairs protein synthesis that is 262 crucial for cognitive processing 263, 264 and for maintaining the integrity of cortical functional maps. 265 Thus, mild CBF reduction may impair cognitive and affective processes, while greater CBF reduction in the context of autoregulatory deficits may cause ischemic injury. The subcortical white matter is particularly sensitive to these changes because it is supplied by terminal arterioles with limited collateral flow, 266 and so susceptible to infarction due to impaired autoregulation. 267 Greater WMH severity may be a marker of broader deficits in perfusion and autoregulation as individuals with greater WMH severity exhibit reduced CBF in both white matter and gray matter regions. [268] [269] [270] Depressed elders with greater WMH severity also exhibit decreased perfusion in the cingulate gyrus, 271 a region involved in cognitive and affective processing. 272 Positron emission tomography, single-photon emission computed tomography and MRI arterial spin labeling have identified CBF differences in midlife adult depressed populations. [273] [274] [275] [276] Advanced age is itself associated with decreased frontotemporal CBF, 277 an effect mediated by vascular risk factors. 278 In LLD, perfusion deficits are more severe, particularly in the medial and lateral PFC, subcortical and temporal structures. 269, [279] [280] [281] [282] [283] Deficits in the dorsolateral PFC may improve with antidepressant response, while other perfusion deficits may not. 281 Others report no change in CBF in antidepressant nonresponders, [284] [285] [286] [287] [288] suggesting that persistently reduced regional CBF may be a biomarker of nonresponse.
Cerebral hypoperfusion is associated not only with Alzheimer's disease and mild cognitive impairment, [289] [290] [291] but also with abnormal performance on specific cognitive tasks. [291] [292] [293] [294] For example, resting hippocampal blood flow is positively correlated with spatial memory performance. 292 Although not specifically a measure of perfusion, reduced arterial CBF predicts slower processing speed, 295 a domain that may mediate other deficits in LLD. 103 Perfusion deficits may thus contribute to the affective and cognitive symptoms observed in LLD. Intriguingly, these data support investigating the utility of agents that may improve perfusion or restore endothelial function. 296 The link between progressive vascular disease and the development and persistence of LLD invites study of the underlying mechanisms by which vascular disease alters brain function in such a way to mediate the development of clinical symptoms. The ultimate goal of this line of study is to develop novel treatments or repurpose existent agents to improve LLD outcomes.
We propose three mechanistic paths to 'vascular depression.' Although the processes of these pathways could proceed independently, they are complementary and interconnected and so may all contribute to LLD (Figure 2 ). For example, inflammation participates in vascular remodeling, accelerates vascular damage 298 and can contribute to perfusion deficits. In turn, regional perfusion deficits adversely affect gray matter function and contribute to the development of WMLs that disrupt regional structural and FC.
We are not proposing a single mechanism underlying LLD. Nonvascular factors clearly contribute to LLD. The same genetic, epigenetic and environmental factors that contribute to depression in younger adults continue to confer vulnerability to depression in later life. Moreover, although alterations in immune and endocrine regulation affect vascular risk, they may also increase the risk of depression through independent mechanisms.
Just as there are nonvascular factors contributing to LLD, there may be additional mechanisms linking vascular disease with LLD. Altered homocysteine metabolism is associated with LLD, 299 with hyperhomocysteinuria potentially contributing to vascular risk by increasing atherosclerosis and endothelial dysfunction. 300 Another example is altered sympatho-adrenomedullary system and hypothalamic-pituitary-adnenal axis function 301 that, among other activities, affects inflammation. 302 These and other mechanisms may contribute to the development or perpetuation of LLD both through vascular and nonvascular pathways and require further study. Such studies would benefit from the incorporation of genomic approaches along with measures of systemic function, thus linking molecular mechanisms with clinically salient measures and outcomes.
Demonstrating that such mechanisms affect neural circuit function, it opens the door for intervention studies examining whether modulation of these mechanisms can improve depression outcomes. There is already preliminary support for using antiinflammatory drugs in depression. Etanercept, a soluble tumor necrosis factor-a receptor, and celecoxib, a cyclo-oxygenase-2 inhibitor, may reduce depressive symptoms in patients with inflammatory diseases 242, 243 and infliximab may improve depression in patients with greater pre-treatment inflammation. 245 Similarly, omega-3 fatty acids are anti-inflammatory and also affect monoamine neurotransmission, 303 suggesting an antidepressant role for omega-3 supplementation. However, recent meta-analyses have not provided strong support for omega-3 supplementation for depression, although larger well designed trials may be warranted. 304, 305 Finally, drugs that modulate the RAS improve cerebral perfusion 297 and may improve cognition, 306-308 although they have not been well studied in depression. We suggest that study of these agents in LLD may produce a novel, targeted pharmacology for the large group of LLD patients who are unresponsive to conventional antidepressants.
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